---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Plasma kallikrein inhibitors"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Plasma kallikrein inhibitors. Topics: Sebetralstat: oral on-demand treatment, Lanadelumab: indication and dosing interval, Berotralstat: oral prophylaxis and dosing, and Lanadelumab and berotralstat: guideline summary of efficacy. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/plasma-kallikrein-inhibitors"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Plasma kallikrein inhibitors

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Plasma Kallikrein Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

### Sebetralstat: oral on-demand treatment

> “EKTERLY is a plasma kallikrein inhibitor that is used for the treatment of acute attacks of hereditary angioedema (HAE)”
> “an oral tablet.”

Source: [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="topic-2.2.2.1.2-2"></a>

### Lanadelumab: indication and dosing interval

> “TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.”
> “The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg administered subcutaneously every 2 weeks (q2wks).”
> “A dosing interval of 300 mg every 4 weeks (q4wks) is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.”

Source: [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Berotralstat: oral prophylaxis and dosing

> “ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.”
> “The recommended dosage of ORLADEYO for adults and pediatric patients 12 years of age and older is 150 mg taken orally once daily with food”
> “ORLADEYO should not be used for treatment of acute HAE attacks.”

Source: [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

### Lanadelumab and berotralstat: guideline summary of efficacy

> “Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.”
> “Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.”
> “Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.”
> “Patients should be aware of delayed onset of action.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
